As it turns out, Amgen (Nasdaq:AMGN) didn't have to stretch too far to seal the deal for oncology biotech company Onyx Pharmaceuticals (Nasdaq:ONXX). While Amgen's initial bid of $120 per Onyx share set off a nearly two-month auction process, in the end it took only an extra $5 per share to complete the deal as there was apparently only passing interest from other Big Pharma players to pay up for Onyx's portfolio of oncology drugs. All in all, while it's a worthwhile deal that helps patch over some near-term growth concerns for Amgen, it's unlikely to be a transformative deal.
The Deal
Amgen and Onyx announced that the two companies had reached a definitive agreement by which Amgen will acquire Onyx for $125 per share in cash. At that price, Amgen is paying an enterprise value of just under $10 billion and a premium of over 45% to the share price before word first broke that Onyx was receiving indications of interest.

SEE: What Makes An M&A Deal Work?
Amgen will be financing this deal with over $8 billion in bank loans priced at LIBOR plus 104bp. The key drug to the deal, multiple myeloma drug Kyprolis, is already approved by the FDA and the sales of the drug (coupled with cutting redundant expenses at Onyx) should lead to Amgen seeing accretion from the deal in 2015.
Advancing The Ball, But Not Changing The Game
While it's possible that Onyx has a hidden gem in preclinical research, this deal looks more like an incremental step forward for Amgen than a transformative deal that will fundamentally change the company's trajectory. In particular, this deal for Onyx will help Amgen get through a challenging growth gap in the 2014-2016 period and better leverage its existing sales and manufacturing infrastructure.

Said differently, Amgen investors should not look at this as a deal on par with Johnson & Johnson's (NYSE:JNJ) acquisition of Cougar or Celgene's (Nasdaq:CELG) acquisition of Abraxis. What's more, while there is potential upside from Onyx's drug palbociclib (licensed to Pfizer (NYSE:PFE)), there are are also risks to Kyprolis from an increasingly competitive myeloma market, including Celgene's portfolio and Phase III drugs from Takeda and Bristol-Myers Squibb (NYSE:BMY).
The Bottom Line
All told, I believe Kyprolis can add $7 billion to $8 billion in net value to Amgen (net of the purchase price), assuming that Amgen can strip out at least half of Onyx's non-R&D operating expenses. The remainder of Onyx's portfolio and pipeline (again, excluding any hidden gems in preclinical development) is likely worth around $500 million to $1.5 billion. Relative to a pre-deal enterprise value of $81.5 billion for Amgen, then, this deal is worthwhile and value-additive, but again not a transformative event.
Amgen share's jumped 9% in early trading. The company is likely to continue to face pointed questions regarding its ability to leverage past deals, but the company does appear to be following a coherent strategy of lower-risk building block deals.
Disclosure – At the time of writing, the author did not own shares of any company mentioned in this article.

Related Articles
  1. Economics

    What are Acquisition Costs?

    A company can recognize acquisition costs as those costs used to buy property and equipment.
  2. Stock Analysis

    3 Resilient Oil Stocks for a Down Market

    Stuck on oil? Take a look at these six stocks—three that present risk vs. three that offer some resiliency.
  3. Economics

    Keep an Eye on These Emerging Economies

    Emerging markets have been hammered lately, but these three countries (and their large and young populations) are worth monitoring.
  4. Stock Analysis

    Is Pepsi (PEP) Still a Safe Bet?

    PepsiCo has long been known as one of the most resilient stocks throughout the broader market. Is this still the case today?
  5. Investing

    The ABCs of Bond ETF Distributions

    How do bond exchange traded fund (ETF) distributions work? It’s a question I get a lot. First, let’s explain what we mean by distributions.
  6. Stock Analysis

    The 5 Best Dividend Stocks in the Healthcare Sector

    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash flows to afford high payouts.
  7. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  8. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  9. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  10. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. How long does it take to execute an M&A deal?

    Even the simplest merger and acquisition (M&A) deals are challenging. It takes a lot for two previously independent enterprises ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!